Base de dados : MEDLINE
Pesquisa : D03.383.606.596 [Categoria DeCS]
Referências encontradas : 205 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 21 ir para página                         

  1 / 205 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16021916
[Au] Autor:Kalsi KK; Smolenski RT; Yacoub MH
[Ad] Endereço:Heart Science Centre, Imperial College at Harefield Hospital, Harefield, Middlesex UB96JH, UK. K.Kalsi@imperial.ac.uk
[Ti] Título:Lidoflazine combined with nucleotide precursors increases ATP content and adenosine production in cardiomyocytes.
[So] Source:Nucleosides Nucleotides Nucleic Acids;24(4):279-82, 2005.
[Is] ISSN:1525-7770
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We have previously identified that the nucleoside transport blocker dipyridamole increases adenosine production but may cause depletion of the nucleotide pool in cardiomyocytes during extended exposure and that this effect was abolished by co-administration of adenine and ribose. The present study aimed to establish whether lidoflazine, a newer generation of nucleoside transport inhibitor with calcium antagonist properties, would cause a similar effect. We conclude that lidoflazine did not affect the nucleotide pool while the combined application of lidoflazine with precursors of nucleotide resynthesis increased ATP concentration and further enhanced adenosine production.
[Mh] Termos MeSH primário: Trifosfato de Adenosina/metabolismo
Adenosina/metabolismo
Lidoflazina/farmacologia
Miócitos Cardíacos/efeitos dos fármacos
Miócitos Cardíacos/metabolismo
Vasodilatadores/farmacologia
[Mh] Termos MeSH secundário: Adenina/farmacologia
Trifosfato de Adenosina/química
Análise de Variância
Animais
Nucleotídeos/química
Ratos
Ribose/farmacologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Nucleotides); 0 (Vasodilator Agents); 681HV46001 (Ribose); 8L70Q75FXE (Adenosine Triphosphate); J4ZHN3HBTE (Lidoflazine); JAC85A2161 (Adenine); K72T3FS567 (Adenosine)
[Em] Mês de entrada:0509
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050719
[St] Status:MEDLINE


  2 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15135665
[Au] Autor:Ridley JM; Dooley PC; Milnes JT; Witchel HJ; Hancox JC
[Ad] Endereço:Department of Physiology and Cardiovascular Research Laboratories, School of Medical Sciences, University Walk, Bristol BS8 1TD, United Kingdom.
[Ti] Título:Lidoflazine is a high affinity blocker of the HERG K(+)channel.
[So] Source:J Mol Cell Cardiol;36(5):701-5, 2004 May.
[Is] ISSN:0022-2828
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Lidoflazine is an antianginal calcium channel blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia. We investigated whether or not lidoflazine inhibits current through the rapid delayed rectifier K(+) channel alpha subunit (encoded by HERG - human ether-a-go-go-related gene), since this channel has been widely linked to drug-induced QT-prolongation. Lidoflazine inhibited potently HERG current (I(HERG)) recorded from HEK 293 cells stably expressing wild-type HERG (IC(50) of approximately 16 nM). It was approximately 13-fold more potent against HERG than was verapamil under similar conditions. On membrane depolarization, I(HERG) inhibition developed gradually, ruling out closed-channel state dependent inhibition. The effect of command voltage on the drug's action suggested that lidoflazine preferentially inhibits activated/open HERG channels. The S6 mutation Y652A largely eliminated the inhibitory action of lidoflazine, whilst the F656A mutation also reduced blocking potency. We conclude: first, that lidoflazine produces high affinity blockade of the alpha subunit of the HERG channel by binding to aromatic amino acid residues within the channel pore and, second, that this is likely to represent the molecular mechanism of QT interval prolongation by this drug.
[Mh] Termos MeSH primário: Lidoflazina/metabolismo
Lidoflazina/farmacologia
Bloqueadores dos Canais de Potássio/metabolismo
Bloqueadores dos Canais de Potássio/farmacologia
Canais de Potássio de Abertura Dependente da Tensão da Membrana/antagonistas & inibidores
Canais de Potássio de Abertura Dependente da Tensão da Membrana/metabolismo
[Mh] Termos MeSH secundário: Linhagem Celular
Canal de Potássio ERG1
Eletrofisiologia
Canais de Potássio Éter-A-Go-Go
Seres Humanos
Lidoflazina/química
Mutação/genética
Fenilalanina/genética
Fenilalanina/metabolismo
Bloqueadores dos Canais de Potássio/química
Canais de Potássio de Abertura Dependente da Tensão da Membrana/genética
Tirosina/genética
Tirosina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (ERG1 Potassium Channel); 0 (Ether-A-Go-Go Potassium Channels); 0 (KCNH2 protein, human); 0 (Potassium Channel Blockers); 0 (Potassium Channels, Voltage-Gated); 42HK56048U (Tyrosine); 47E5O17Y3R (Phenylalanine); J4ZHN3HBTE (Lidoflazine)
[Em] Mês de entrada:0412
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040512
[St] Status:MEDLINE


  3 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9259060
[Au] Autor:Vaagenes P; Safar P; Moossy J; Rao G; Diven W; Ravi C; Arfors K
[Ad] Endereço:Safar Center for Resuscitation Research (SCRR), Department of Anesthesiology and Critical Care Medicine, University of Pittsburg Medical Center (UPMC), PA 15260, USA.
[Ti] Título:Asphyxiation versus ventricular fibrillation cardiac arrest in dogs. Differences in cerebral resuscitation effects--a preliminary study.
[So] Source:Resuscitation;35(1):41-52, 1997 Aug.
[Is] ISSN:0300-9572
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: We explored the hypothesis that brain damage after cardiac arrest caused by ventricular fibrillation (VF) needs different therapies than that after asphyxiation, which has been studied less thoroughly. In 67 healthy mongrel dogs of both sexes cardiac arrest (at normothermia) by ventricular fibrillation (no blood flow lasting 10 min) or asphyxiation (no blood flow lasting 7 min) was reversed by normothermic external cardiopulmonary resuscitation, followed by intermittent positive-pressure ventilation for 20 h, and intensive care to 96 h. To ameliorate ischemic brain damage, the calcium entry blocker lidoflazine or a solution of free radical scavengers (mannitol and L-methionine in dextran 40) plus magnesium sulphate, was given intravenously immediately upon restoration of spontaneous circulation. Outcome was evaluated as functional deficit, brain creatine kinase (CK) leakage into the cerebrospinal fluid (CSF) and brain morphologic changes. Lidoflazine seemed to improve cerebral outcome after VF but not after asphyxiation. Free radical scavengers plus magnesium sulphate seemed to improve cerebral outcome after asphyxiation, but not after VF. After VF, scattered ischemic neuronal changes in multiple brain regions dominated, and total brain histopathologic damage scores correlated with final neurologic deficit scores at 96 h (r = 0.66) and with peak CK levels in CSF (r = 0.81). After asphyxiation, in addition to the same ischemic neuronal changes, microinfarcts occurred, and there was no correlation between total brain histopathologic damage scores and neurologic deficit scores or CK levels in CSF. CONCLUSIONS: Different mechanisms of cardiac arrest, which cause different morphologic patterns of brain damage, may need different cerebral resuscitation treatments.
[Mh] Termos MeSH primário: Asfixia/complicações
Isquemia Encefálica/prevenção & controle
Reanimação Cardiopulmonar/métodos
Parada Cardíaca/etiologia
Fibrilação Ventricular/complicações
[Mh] Termos MeSH secundário: Animais
Isquemia Encefálica/etiologia
Bloqueadores dos Canais de Cálcio/uso terapêutico
Cães
Feminino
Depuradores de Radicais Livres/uso terapêutico
Parada Cardíaca/terapia
Lidoflazina/uso terapêutico
Sulfato de Magnésio/uso terapêutico
Masculino
Respiração com Pressão Positiva
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Free Radical Scavengers); 7487-88-9 (Magnesium Sulfate); J4ZHN3HBTE (Lidoflazine)
[Em] Mês de entrada:9709
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970801
[St] Status:MEDLINE


  4 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9058219
[Au] Autor:De Hert SG; Rodrigus IE; Haenen LR; Ten Broecke PW; Boeckxstaens CJ; Gillebert TC
[Ad] Endereço:Department of Anesthesiology, University Hospital of Antwerp, Belgium.
[Ti] Título:Effects of lidoflazine on left ventricular function in patients.
[So] Source:J Cardiothorac Vasc Anesth;11(1):42-8, 1997 Feb.
[Is] ISSN:1053-0770
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The present study evaluated the effects of the nucleoside transport inhibitor, lidoflazine, at a dose of 1 mg/kg, on left ventricular function. DESIGN: Patients were randomly assigned to receive either lidoflazine or saline in a double-blind manner. SETTING: A university hospital. PARTICIPANTS: The study was performed in 32 patients scheduled for elective coronary artery bypass surgery. INTERVENTIONS: Left ventricular pressures were measured with fluid-filled catheters. Data were digitally recorded during pressure elevation induced by tilt-up of the legs. Transgastric short-axis echocardiographic views of the left ventricle were simultaneously recorded on videotape. Systolic function was evaluated with the slope (Ees, mmHg/mL) of the systolic pressure-volume relationship. Diastolic function was evaluated with the chamber stiffness constant (Kc, mmHg/mL) of the diastolic pressure-volume relationship. Cardiac function was assessed at baseline and after administration of either lidoflazine (group A [n = 16]) or placebo (group B [n = 16]). Data were compared using two-factor analysis of variance. MEASUREMENTS AND MAIN RESULTS: At baseline, diastolic and systolic function were comparable in both groups. Lidoflazine increased Kc from 0.079 +/- 0.015 to 0.125 +/- 0.017 mmHg/mL and decreased Ees from 2.481 +/- 0.213 to 1.217 +/- 0.211 mmHg/mL (p = 0.009 and p = 0.004, respectively). None of these changes occurred when placebo was administered. CONCLUSIONS: Administration of lidoflazine before the start of cardiopulmonary bypass impaired left ventricular systolic function but also increased diastolic stiffness.
[Mh] Termos MeSH primário: Lidoflazina/farmacologia
Vasodilatadores/farmacologia
Função Ventricular Esquerda/efeitos dos fármacos
[Mh] Termos MeSH secundário: Idoso
Ponte de Artéria Coronária
Método Duplo-Cego
Feminino
Hemodinâmica
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Vasodilator Agents); J4ZHN3HBTE (Lidoflazine)
[Em] Mês de entrada:9705
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970201
[St] Status:MEDLINE


  5 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8931932
[Au] Autor:Chiarini A; Rampa A; Budriesi R; Bisi A; Fabbri G; Valenti P
[Ad] Endereço:Department of Pharmaceutical Sciences, University of Bologna, Italy.
[Ti] Título:1,4-Dihydropyridines bearing a pharmacophoric fragment of lidoflazine.
[So] Source:Bioorg Med Chem;4(10):1629-35, 1996 Oct.
[Is] ISSN:0968-0896
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A series of 1,4-dihydropyridines bearing a pharmacophoric fragment of lidoflazine was synthesized. The compounds were evaluated for inotropic, chronotropic, and calcium antagonist activities. All compounds behave as inotropic and chronotropic agents, except for compounds 4b, 5a, and 5b, which exhibit a rather weak calcium antagonism in vascular smooth muscle (like aorta). Compound 5b is about twofold more potent in decreasing both chronotropy and inotropy, while compound 5c is about fivefold more potent in decreasing inotropy than nifedipine. Moreover, compound 5b is the most potent calcium antagonist derivative of the series.
[Mh] Termos MeSH primário: Bloqueadores dos Canais de Cálcio/química
Di-Hidropiridinas/química
Lidoflazina/química
Vasodilatadores/química
[Mh] Termos MeSH secundário: Animais
Aorta Torácica/efeitos dos fármacos
Aorta Torácica/metabolismo
Bloqueadores dos Canais de Cálcio/farmacologia
Di-Hidropiridinas/farmacologia
Feminino
Cobaias
Coração/efeitos dos fármacos
Lidoflazina/farmacologia
Masculino
Contração Miocárdica/efeitos dos fármacos
Vasodilatadores/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Dihydropyridines); 0 (Vasodilator Agents); 7M8K3P6I89 (1,4-dihydropyridine); J4ZHN3HBTE (Lidoflazine)
[Em] Mês de entrada:9703
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:961001
[St] Status:MEDLINE


  6 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8796493
[Au] Autor:Shively M; Norton L; Mendez K
[Ad] Endereço:Veterans Affairs Medical Center, San Diego, California, USA.
[Ti] Título:Neurologic outcomes after cardiac resuscitation.
[So] Source:J Cardiovasc Nurs;10(4):93-6, 1996 Jul.
[Is] ISSN:0889-4655
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this research utilization article is to familiarize cardiovascular nurses with the Brain Resuscitation Clinical Trials (BRCTs) I and II and discuss the application of these trials to nursing practice. The BRCTs are a series of studies that examine the effects of selected interventions on neurologic outcome after cardiac arrest.
[Mh] Termos MeSH primário: Lesões Encefálicas/prevenção & controle
Reanimação Cardiopulmonar
Parada Cardíaca/complicações
[Mh] Termos MeSH secundário: Bloqueadores dos Canais de Cálcio/uso terapêutico
Reanimação Cardiopulmonar/enfermagem
Parada Cardíaca/mortalidade
Parada Cardíaca/enfermagem
Parada Cardíaca/terapia
Seres Humanos
Hipnóticos e Sedativos/uso terapêutico
Lidoflazina/uso terapêutico
Tiopental/uso terapêutico
Índices de Gravidade do Trauma
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Hypnotics and Sedatives); 0 (Vasodilator Agents); J4ZHN3HBTE (Lidoflazine); JI8Z5M7NA3 (Thiopental)
[Em] Mês de entrada:9612
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:960701
[St] Status:MEDLINE


  7 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8572777
[Au] Autor:Flameng WJ; Herijgers P; Szécsi J; Sergeant PT; Daenen WJ; Scheys I
[Ad] Endereço:Department of Cardiac Surgery, Katholieke Universiteit Leuven, Belgium.
[Ti] Título:Determinants of early and late results of combined valve operations and coronary artery bypass grafting.
[So] Source:Ann Thorac Surg;61(2):621-8, 1996 Feb.
[Is] ISSN:0003-4975
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Factors determining the outcome of operative correction of valvular abnormalities combined with coronary artery bypass grafting are still incompletely defined. METHODS: Determinants of early and late (more than 90 days) deaths and event-free survival were studied for combined valve operations and coronary artery bypass grafting in 741 patients using multivariate analysis. RESULTS: Ninety-day survival probability was 89% (95% confidence interval, 87% to 92%). Preoperative risk factors for early death were age, female sex, renal failure, New York Heart Association class IV or V, and mitral insufficiency. The operative risk factor was the duration of aortic cross-clamping. Five- and 10-year survival probabilities were 74% (95% confidence interval, 71% to 78%) and 43% (95% confidence interval, 36% to 50%), respectively. Preoperative risk factors for late death were age, preoperative renal failure, New York Heart Association class IV or V, vessel disease, and nonsinus rhythm. Five- and 10-year event-free survival probabilities were 57% (95% confidence interval, 53% to 61%) and 23% (95% confidence interval, 17% to 28%), respectively. Preoperative risk factors for non-event-free survival were age, female sex, reduced left ventricular function, mitral regurgitation, and pacemaker rhythm. CONCLUSION: The demographic factors of age and female sex; the comorbid condition of renal failure; the cardiac conditions of advanced New York Heart Association class, left ventricular function, mitral regurgitation, vessel disease, and cardiac rhythm; and the operative condition of ischemia time are the most important predictors of clinical outcome after combined valve operations and coronary artery bypass grafting.
[Mh] Termos MeSH primário: Ponte de Artéria Coronária
Doença das Coronárias/cirurgia
Doenças das Valvas Cardíacas/cirurgia
Próteses Valvulares Cardíacas
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Valva Aórtica/cirurgia
Ponte de Artéria Coronária/mortalidade
Doença das Coronárias/complicações
Doença das Coronárias/mortalidade
Feminino
Doenças das Valvas Cardíacas/complicações
Doenças das Valvas Cardíacas/mortalidade
Mortalidade Hospitalar
Seres Humanos
Falência Renal Crônica/complicações
Lidoflazina/uso terapêutico
Masculino
Meia-Idade
Valva Mitral/cirurgia
Análise Multivariada
Pré-Medicação
Modelos de Riscos Proporcionais
Fatores de Risco
Fatores Sexuais
Análise de Sobrevida
Resultado do Tratamento
Valva Tricúspide/cirurgia
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); J4ZHN3HBTE (Lidoflazine)
[Em] Mês de entrada:9603
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:960201
[St] Status:MEDLINE


  8 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8001370
[Au] Autor:Rogove HJ; Safar P; Sutton-Tyrrell K; Abramson NS
[Ad] Endereço:Department of Anesthesiology, University of Pittsburgh Medical Center, PA. 15260.
[Ti] Título:Old age does not negate good cerebral outcome after cardiopulmonary resuscitation: analyses from the brain resuscitation clinical trials. The Brain Resuscitation Clinical Trial I and II Study Groups.
[So] Source:Crit Care Med;23(1):18-25, 1995 Jan.
[Is] ISSN:0090-3493
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess survival after cardiac arrest and to determine whether age is an independent determinant of late mortality or poor neurologic outcome. DESIGN: Analyses using results of Brain Resuscitation Clinical Trial I (1979 to 1984) and Brain Resuscitation Clinical Trial II (1984 to 1989), two randomized, double-blind studies of outcome following cardiac arrest. SETTING: A multicenter study in 12 acute care hospitals in nine countries (Brain Resuscitation Clinical Trial I), and 24 hospitals in eight countries (Brain Resuscitation Clinical Trial II). PATIENTS: A total of 774 patients who were initially comatose after successful resuscitation from cardiac arrest. The analyses include both in- and out-of-hospital cardiac arrests. RESULTS: The 6-month mortality rate for the entire group was 81%. Mortality rate was 94% for the oldest group (> 80 yrs) compared with 68% for the youngest group (< or = 45 yrs) (p < .01). Other independent predictors of mortality were history of diabetes mellitus, inhospital arrests, arrest time of > 5 mins, history of congestive heart failure, a noncardiac cause of arrest, and cardiopulmonary resuscitation time of > 20 mins. Of the 774 patients, 27% recovered good neurologic function. There was no statistically significant difference in neurologic recovery rates by age. Multivariate analysis showed that independent predictors of good neurologic recovery were: no history of diabetes mellitus, a cardiac cause of arrest, short arrest time, and short cardiopulmonary resuscitation time. CONCLUSION: Increasing age was a factor in postresuscitation mortality, but was not an independent predictor of poor neurologic outcome.
[Mh] Termos MeSH primário: Reanimação Cardiopulmonar
Coma/terapia
Parada Cardíaca/terapia
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Reanimação Cardiopulmonar/mortalidade
Coma/etiologia
Coma/mortalidade
Método Duplo-Cego
Feminino
Escala de Coma de Glasgow
Parada Cardíaca/complicações
Parada Cardíaca/mortalidade
Seres Humanos
Lidoflazina/uso terapêutico
Masculino
Meia-Idade
Exame Neurológico
Prognóstico
Fatores de Risco
Tiopental/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
J4ZHN3HBTE (Lidoflazine); JI8Z5M7NA3 (Thiopental)
[Em] Mês de entrada:9501
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:950101
[St] Status:MEDLINE


  9 / 205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7739233
[Au] Autor:Akpinar B; Vanerman H; Wellens F
[Ad] Endereço:O.L.V. Hospital, Department of Thoracic and Cardiovascular Surgery, Aalst, Belgium.
[Ti] Título:Lidoflazine and myocardial protection.
[So] Source:J Thorac Cardiovasc Surg;109(5):1013-4; discussion 1015, 1995 May.
[Is] ISSN:0022-5223
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Parada Cardíaca Induzida
Coração/efeitos dos fármacos
Lidoflazina/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
J4ZHN3HBTE (Lidoflazine)
[Em] Mês de entrada:9506
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:950501
[St] Status:MEDLINE


  10 / 205 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:7482916
[Au] Autor:Flameng W
[Ad] Endereço:Department of Cardiac Surgery, Katholieke Universiteit Leuven, Belgium.
[Ti] Título:Intermittent ischemia of the heart.
[So] Source:Transplant Proc;27(5):2791-2, 1995 Oct.
[Is] ISSN:0041-1345
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Ponte de Artéria Coronária
Doença das Coronárias/fisiopatologia
Vasos Coronários/fisiopatologia
Isquemia Miocárdica/fisiopatologia
[Mh] Termos MeSH secundário: Adenosina/agonistas
Adenosina/fisiologia
Aorta/fisiologia
Aorta/fisiopatologia
Vasos Coronários/fisiologia
Seres Humanos
Lidoflazina/uso terapêutico
Contração Miocárdica
Necrose
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Vasodilator Agents); J4ZHN3HBTE (Lidoflazine); K72T3FS567 (Adenosine)
[Em] Mês de entrada:9512
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:951001
[St] Status:MEDLINE



página 1 de 21 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde